A Non-interventional Real-World Study on Dose Modifications of Enfortumab Vedotin (EV) in Combination with Pembrolizumab (P) in Previously Untreated Patients with Advanced Urothelial Carcinoma in Germany First published 21/02/2025 Last updated 16/07/2026 EU PAS number:EUPAS1000000467 Study Discontinued